- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CMPS
Recent news which mentions CMPS
From Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
July 18, 2023
Tickers
CMPS
From Benzinga
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 12, 2023
From Benzinga
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
July 11, 2023
From Benzinga
Top 5 Health Care Stocks That May Collapse This Quarter
July 10, 2023
From Benzinga
Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 07, 2023
From Benzinga
From Benzinga
Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures
July 06, 2023
Tickers
CMPS
From Benzinga
From Benzinga
Tickers
CMPS
From Motley Fool
The 3 Best Psychedelic Stocks to Buy Now
June 29, 2023
From InvestorPlace
TOMS Shoes founder is pledging $100 million for psychedelic research – Here’s why he’s doing it.
June 21, 2023
From MarketWatch
From Benzinga
From Benzinga
From Benzinga
Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients
May 26, 2023
From MarketWatch
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
May 15, 2023
From Benzinga
COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials
May 11, 2023
Tickers
CMPS
From Benzinga
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
May 11, 2023
From Benzinga
Tickers
CMPS
From Motley Fool
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
May 08, 2023
From Benzinga
This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why
May 06, 2023
Tickers
CMPS
From Motley Fool
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
May 02, 2023
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.